Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Results of Operations and Financial Condition

Item2.02 Results of Operations and Financial Condition.

Although it has not finalized its full financial results for the
fourth quarter and fiscal year ended December31, 2016, Agios
Pharmaceuticals, Inc. (the Company) announced on January9, 2017,
that it expects to report that it had approximately $574 million
of cash, cash equivalents and marketable securities as of
December31, 2016.

The information contained in Item2.02 of this Form 8-K is
unaudited and preliminary, and does not present all information
necessary for an understanding of the Companys financial
condition as of December31, 2016 and its results of operations
for the three months and year ended December31, 2016. The audit
of the Companys consolidated financial statements for the year
ended December31, 2016 is ongoing and could result in changes to
the information set forth above.

The information in this Item2.02 shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended (the Securities Act), or the Exchange Act, except as
expressly set forth by specific reference in such a filing.

Item7.01 Regulation FD Disclosure.

On January9, 2017, the Company intends to make a slide
presentation at the 35th Annual J.P. Morgan Healthcare
Conference. A form of the slide presentation is being furnished
as Exhibit 99.1 to this Current Report on Form8-K.

The information responsive to Item7.01 of this Form 8-K,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section18 of the Exchange Act or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

Item8.01 Other Events.

On January9, 2017, the Company issued a press release outlining
its 2017 milestones for its development programs and research
pipeline, which will be discussed at the Companys presentation at
the 35th Annual J.P. Morgan Healthcare Conference on January9,
2017. The full text of the press release issued in connection
with this announcement is filed as Exhibit 99.2 to this Current
Report on Form 8-K and is incorporated herein by reference.

Forward Looking Statements

This Current Report on Form 8-K and the exhibits attached hereto
contain forward-looking statements of the Company that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this Current Report
on Form8-K and the exhibits attached hereto, are forward-looking
statements. The words anticipate, believe, estimate, expect,
intend, may, plan, predict, project, target, potential, will,
would, could, should, continue, contemplate, or the negative of
these terms or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking
statements include, among others, statements about: the Companys
estimates regarding its balance of cash, cash equivalents and
marketable securities for the year ended December 31, 2016 and
other expectations regarding its business, plans, prospects and
strategies. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the
forward-looking statements that the Company makes due to a number
of important factors, including those Risk Factors discussed in
the Companys Quarterly Report on Form 10-Q for the quarter ended
September 30, 2016, and other filings that the Company may make
with the Securities and Exchange Commission in the future. Any
forward-looking statements contained in this Current Report on
Form 8-K speak only as of the date hereof, and the Company
expressly disclaims any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.

Item9.01 Financial Statements and Exhibits.

(d) The following exhibits are included in this report:

About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Recent Trading Information

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closed its last trading session down -4.65 at 42.85 with 555,812 shares trading hands.